摘要
目的分析评价全国(未包括香港、澳门特别行政区和台湾地区)2009～2010年接种甲型H1N1流行性感冒(甲流)疫苗后,疑似预防接种异常反应(Adverse Events Following Immunization,AEFI)中过敏性紫癜(Henoch-schnlein Purpura,HSP)的发生风险。方法通过中国AEFI信息管理系统,收集2009年9月21日～2010年7月31日开展甲流疫苗接种活动后,截止2010年11月20日甲流疫苗HSP个案信息,采用描述性方法进行流行病学分析。结果接种甲流疫苗期间,中国共报告接种甲流疫苗后HSP112例,报告发生率为1.12/100万剂次,报告住院率64.29%。其中,报告异常反应中HSP 103例,报告发生率为1.03/100万剂次;≤9岁儿童报告发生率为3.36/100万剂次。结论接种甲流疫苗后发生HSP异常反应极为罕见,远低于HSP的基础发生率;无证据表明接种甲流疫苗会增加HSP的发生风险。
Objective To analyze the occurrence of Henoch-schonlein purpura（HSP）following the Influenza A（H1N1）vaccine immunization in China during 2009-2010, and to evaluate the risk of HSP following immunization and the response for HSP. Methods Data on HSP following Influenza A（H1N1）vaccine immunization were collected through China AEFI information system by November 20, 2010. The number of doses administered was collected. The descriptive methodology was used in the study. Results 100.01 million doses were administered between September 21 and November 20, 2010, and 112 HSP cases（rate： 1.12 per million doses） were reported, with a hospitalization rate of 64.29%. Among children aged≤ 9 years, rate of HSP was 3.36 per million. Conclusions HSP associated with influenza A （H1NI） was rare, the incidence was lower than the baseline data Vaccination of Influenza A （HINI） vaccine did not increase the risk of HSP.
出处
《中国疫苗和免疫》
CAS
2011年第2期122-127,132,共7页
Chinese Journal of Vaccines and Immunization
